Immix Biopharma Inc. (NASDAQ:IMMX) Stock Soars IMX-110 Demonstrated Improved Survival

May 23, 2022

Immix Biopharma Inc. (NASDAQ: IMMX) was up 30% after the biopharmaceutical firm pioneering Tissue-Specific Therapeutics targeting immune-dysregulated and oncology diseases announced positive preliminary trial data showing that after one treatment cycle, its lead candidate IMX-110 had 75% survival compared to 0% survival for FDA-approved drug Trabectedin that is sold as YONDELIS. Trading Data On Friday, IMMX stock gained 30.06% to $2.12 with more than 111.65 million shares, compared to its…